Allarity Therapeutics, Inc. (ALLR)
Develops personalized cancer drugs paired with diagnostic tests to match patients to treatments.
$1.18-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+16.8%
The outlook
ALLR trades well below its 50- and 200-day moving averages, sitting near the lower end of its 52-week range. Analyst coverage shows a wide gap, with the average price target sitting roughly 7.7× the current price—a substantial disconnect that reflects high uncertainty around the stock's prospects. The overall sentiment leans bearish.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range26% of the way from its 52-week low to high
Price targetAvg target +769% vs current price
Market cap
$18.8M
52-wk high
$2.35
52-wk low
$0.77
50-day avg
$1.39
200-day avg
$1.24
Trailing P/E
—